JPWO2018211115A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2018211115A5
JPWO2018211115A5 JP2019563540A JP2019563540A JPWO2018211115A5 JP WO2018211115 A5 JPWO2018211115 A5 JP WO2018211115A5 JP 2019563540 A JP2019563540 A JP 2019563540A JP 2019563540 A JP2019563540 A JP 2019563540A JP WO2018211115 A5 JPWO2018211115 A5 JP WO2018211115A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
cells
polypeptide construct
use according
rhob
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019563540A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020520367A (ja
JP7486953B2 (ja
JP2020520367A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/063210 external-priority patent/WO2018211115A1/en
Publication of JP2020520367A publication Critical patent/JP2020520367A/ja
Publication of JPWO2018211115A5 publication Critical patent/JPWO2018211115A5/ja
Publication of JP2020520367A5 publication Critical patent/JP2020520367A5/ja
Application granted granted Critical
Publication of JP7486953B2 publication Critical patent/JP7486953B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019563540A 2017-05-18 2018-05-18 細胞標的化療法のための組成物および方法 Active JP7486953B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762508272P 2017-05-18 2017-05-18
US62/508,272 2017-05-18
US201762508833P 2017-05-19 2017-05-19
US62/508,833 2017-05-19
PCT/EP2018/063210 WO2018211115A1 (en) 2017-05-18 2018-05-18 Compositions and methods for cell targeting therapies

Publications (4)

Publication Number Publication Date
JP2020520367A JP2020520367A (ja) 2020-07-09
JPWO2018211115A5 true JPWO2018211115A5 (https=) 2023-04-18
JP2020520367A5 JP2020520367A5 (https=) 2023-04-18
JP7486953B2 JP7486953B2 (ja) 2024-05-20

Family

ID=62492593

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019563540A Active JP7486953B2 (ja) 2017-05-18 2018-05-18 細胞標的化療法のための組成物および方法

Country Status (7)

Country Link
US (1) US12161669B2 (https=)
EP (1) EP3624823A1 (https=)
JP (1) JP7486953B2 (https=)
CN (1) CN110944658A (https=)
AU (1) AU2018268087B2 (https=)
CA (1) CA3063807A1 (https=)
WO (1) WO2018211115A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2831109B1 (en) 2012-03-28 2017-12-06 Gadeta B.V. Combinatorial gamma 9 delta 2 t cell receptor chain exchange
JP2019525898A (ja) 2016-06-10 2019-09-12 ガデタ・ベー・フェー ヒト白血球抗原拘束ガンマデルタt細胞受容体及びその使用方法
JP7486953B2 (ja) 2017-05-18 2024-05-20 ユーエムセー・ユトレヒト・ホールディング・ベー・フェー 細胞標的化療法のための組成物および方法
WO2019156566A1 (en) * 2018-02-12 2019-08-15 Umc Utrecht Holding B.V. Bispecific molecules comprising gamma-delta tcr and t-cell or nk cell binding domain
WO2019219979A1 (en) * 2018-05-18 2019-11-21 Umc Utrecht Holding B.V. Compositions and methods for cell targeting therapies
CN112255395B (zh) * 2020-12-23 2021-06-18 中生北控生物科技股份有限公司 一种消除脂血样本中乳糜干扰的方法和免疫浊度法试剂盒及应用
WO2022136681A1 (en) 2020-12-23 2022-06-30 Gadeta B.V. Chimeric, transmembrane proteins with bidirectional signalling activity
US20240115705A1 (en) * 2021-02-08 2024-04-11 The J. Gladstone Institutes, a testamentary trust established under the will of J. David Gladstone Regulation of Butyrophilin subfamily 3 member A1 (BTN3A1, CD277)
KR20230159851A (ko) * 2021-03-22 2023-11-22 주노 쎄러퓨티크스 인코퍼레이티드 치료 세포 조성물의 효력을 결정하는 방법
WO2022214707A1 (en) 2021-04-09 2022-10-13 Gadeta B.V. Cellular reporter and methods of using the same
US20260014199A1 (en) 2022-06-17 2026-01-15 Gadeta B.V. Modified immune cells
GB202406837D0 (en) * 2024-05-14 2024-06-26 Immunocore Ltd Screening methods

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5260223A (en) 1986-07-03 1993-11-09 President & Fellows Of Harvard College Methods for detection of human gamma, γ T cell receptor
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
CA2096222C (en) 1990-11-13 1998-12-29 Stephen D. Lupton Bifunctional selectable fusion genes
FR2698880B1 (fr) 1992-11-25 1995-02-24 Inst Nat Sante Rech Med Procédé de production de récepteurs T solubles, produits ainsi obtenus et leur utilisation dans des compositions diagnostiques ou thérapeutiques.
WO1994028143A1 (en) 1993-05-21 1994-12-08 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US5885827A (en) 1996-01-23 1999-03-23 The Regents Of The Universtiy Of California Eukaryotic high rate mutagenesis system
US6207455B1 (en) 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
JP4390860B2 (ja) 1997-05-13 2009-12-24 ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル レンチウイルスをベースにした遺伝子転移ベクター
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
GB9810099D0 (en) 1998-05-11 1998-07-08 Isis Innovation Novel molecule and diagnostic method
WO1999060120A2 (en) 1998-05-19 1999-11-25 Avidex Limited Soluble t cell receptor
DE19909769A1 (de) 1999-03-05 2000-09-07 Bundesrepublik Deutschland Let Von SIVagm abgeleitete lentivirale Vektoren, Verfahren zu ihrer Herstellung und ihre Verwendung zur Genübertragung in Säugerzellen
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
CA2406864A1 (en) 2000-02-24 2001-08-30 Life Technologies Corporation Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
JP2001332430A (ja) 2000-05-22 2001-11-30 Murata Mfg Co Ltd トランス
US20030031678A1 (en) 2000-09-19 2003-02-13 Shujath Ali Compositions and methods relating to prostate specific genes and proteins
CN1280307C (zh) 2001-04-03 2006-10-18 宝生物工程株式会社 细胞毒性t淋巴细胞
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
WO2004016225A2 (en) 2002-08-19 2004-02-26 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2003060097A2 (en) 2002-01-10 2003-07-24 National Jewish Medical And Research Center USE OF SOLUBLE Ϝδ T CELL RECEPTORS FOR REGULATING T CELL FUNCTION
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
US7892745B2 (en) 2003-04-24 2011-02-22 Xdx, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
JP4516916B2 (ja) 2003-07-11 2010-08-04 昇志 佐藤 リビン由来のhla−a24結合性癌抗原ペプチド
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US8361794B2 (en) 2004-06-29 2013-01-29 Immunocore Limited Cells expressing a modified T cell receptor
GB0425732D0 (en) 2004-11-23 2004-12-22 Avidex Ltd Gamma-delta t cell receptors
GB0506760D0 (en) 2005-04-01 2005-05-11 Avidex Ltd High affinity HIV TCRS
EP1941028A2 (en) 2005-08-08 2008-07-09 Fondazione Centro San Raffaele Del Monte Tabor Use of common gamma chain cytokines for the visualization, isolation and genetic modification of memory t lymphocytes.
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
BRPI0807952A2 (pt) 2007-02-20 2014-06-10 Anaptysbio Inc Sistemas de hipermutação somática
ES2622505T3 (es) 2008-05-09 2017-07-06 Agency For Science, Technology And Research Receptor de linfocito T (RLT) exógeno reactivo contra epítopo de VHB y usos del mismo
CN102272153B (zh) 2008-11-24 2015-04-15 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 高亲和力t细胞受体及其应用
WO2010087335A1 (ja) 2009-01-27 2010-08-05 学校法人産業医科大学 T細胞抗原受容体遺伝子、受容体α鎖及びβ鎖発現用ベクター並びに細胞障害性T細胞
EP2496244B8 (en) 2009-11-02 2017-11-22 Emory University Drug resistant immunotherapy for treatment of a cancer
CN102453701B (zh) 2010-10-26 2014-08-13 中国医学科学院基础医学研究所 基因修饰CDR3δ移植型γδT淋巴细胞及其抑癌用途
US20150353643A1 (en) * 2013-09-24 2015-12-10 Universite De La Mediterranee - Aix-Marseille Ii Anti-cd277 antibodies and uses thereof
ES2588730T3 (es) 2011-03-17 2016-11-04 Miltenyi Biotec Gmbh Preparados celulares agotados en lo que respecta a TCRalfa/beta
CN102532269B (zh) 2011-05-16 2014-07-09 中国医学科学院基础医学研究所 γδT淋巴细胞中δ1链互补决定域3的优势序列及其TCR受体转染细胞与应用
CN103635573B (zh) 2011-05-19 2016-05-11 分子医学研究所 包含γδT细胞的淋巴细胞系、其组合物及生产方法
EP3549611B1 (en) 2011-07-29 2021-06-30 The Trustees of the University of Pennsylvania Switch costimulatory receptors
EP2831109B1 (en) 2012-03-28 2017-12-06 Gadeta B.V. Combinatorial gamma 9 delta 2 t cell receptor chain exchange
EP2906684B8 (en) 2012-10-10 2020-09-02 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
US20150259645A1 (en) 2012-11-08 2015-09-17 INSERM (Institut National de la Santé et de la Recherche Médicale Method for inducing il-2-free proliferation of gamma delta t cells
WO2014179202A1 (en) 2013-05-02 2014-11-06 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosis of celiac disease
WO2015063069A1 (en) 2013-10-28 2015-05-07 Benjamin Felder Chimeric antigen receptors with antigen binding domains derived from gamma delta t cell receptors
CN106103711A (zh) 2013-11-21 2016-11-09 组库创世纪株式会社 T细胞受体和b细胞受体库分析系统及其在治疗和诊断中的应用
JP2017505819A (ja) 2014-02-04 2017-02-23 カイト ファーマ インコーポレイテッドKite Pharma, Inc B細胞悪性腫瘍及び他のがんの治療に有用な自己t細胞を産生する方法、並びにその組成物
EP3144388B1 (en) 2014-05-13 2020-07-01 Chugai Seiyaku Kabushiki Kaisha T cell-redirecting antigen-binding molecule for cells having immunosuppression function
GB201506423D0 (en) 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
US10280188B2 (en) 2015-02-02 2019-05-07 Nagasaki University Fluorine-containing bisphosphonic acid derivative and use thereof
WO2016195086A1 (ja) 2015-06-05 2016-12-08 医療法人社団 滉志会 アレルギー性疾患の治療薬
PT3328894T (pt) 2015-08-06 2019-02-13 Agency Science Tech & Res Anticorpos de cadeia comum gama/il2rbeta
JP2018531593A (ja) 2015-09-11 2018-11-01 アジェナス インコーポレイテッド 操作された宿主細胞及びそれらの使用方法
CN105296431B (zh) 2015-11-26 2018-10-09 北京佳德和细胞治疗技术有限公司 肿瘤结合特异性γδTCR基因修饰的αβT细胞及其抑癌用途
US12297427B2 (en) 2015-12-04 2025-05-13 St. Jude Children's Research Hospital, Inc. Cloning and expression system for T-cell receptors
EP3454870A4 (en) * 2016-05-12 2020-03-04 Adicet Bio Inc. METHOD FOR SELECTIVE EXPANSION OF GAMMA DELTA T CELL POPULATIONS AND COMPOSITIONS THEREOF
JP2019525898A (ja) 2016-06-10 2019-09-12 ガデタ・ベー・フェー ヒト白血球抗原拘束ガンマデルタt細胞受容体及びその使用方法
WO2018162563A1 (en) 2017-03-07 2018-09-13 Universität Basel Mr1 restricted t cell receptors for cancer immunotherapy
JP7486953B2 (ja) 2017-05-18 2024-05-20 ユーエムセー・ユトレヒト・ホールディング・ベー・フェー 細胞標的化療法のための組成物および方法
WO2019156566A1 (en) 2018-02-12 2019-08-15 Umc Utrecht Holding B.V. Bispecific molecules comprising gamma-delta tcr and t-cell or nk cell binding domain
WO2019219979A1 (en) 2018-05-18 2019-11-21 Umc Utrecht Holding B.V. Compositions and methods for cell targeting therapies

Similar Documents

Publication Publication Date Title
JP7421194B2 (ja) 改変ナチュラルキラー細胞及びその使用
JP7181917B2 (ja) 濃縮された腫瘍反応性t細胞集団を腫瘍から作製する方法
Rozenbaum et al. Gamma-delta CAR-T cells show CAR-directed and independent activity against leukemia
US12275787B2 (en) Chimeric antigen receptors (CARs), compositions and methods thereof
Lim et al. GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo
Gargett et al. Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2
JP6971986B2 (ja) 免疫療法の抗腫瘍活性を高めるための間葉系幹細胞
TWI410495B (zh) 新穎之人類t細胞群
CN105873952A (zh) 经修饰的造血干细胞/祖细胞和非t效应细胞及其用途
CN106459924A (zh) 用于疗法中的嵌合抗原受体(car)及其制备方法
WO2019189115A1 (ja) ケモカインレセプターと細胞接着分子を発現するcd3陰性細胞の集団、およびその利用並びにその製造方法
JPWO2018211115A5 (https=)
Van Caeneghem et al. Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities
US20220125846A1 (en) Tumor-activated alloreactive and xenoreactive t cells and their use in immunotherapy against cancer
US20240139322A1 (en) Compositions and methods to reduce therapeutic t cell toxicity
JP2022163062A (ja) Ccr2+造血幹細胞は養子細胞療法におけるt細胞活性化を媒介する
JP2022515144A (ja) オフザシェルフのダブルネガティブt細胞の産生および治療的使用
ES3036043T3 (en) Methods for enhancing tcr alpha beta+ cell depletion efficiency
JP2025518983A (ja) Cd16高cd57高nk-92mi細胞
WO2024120506A1 (zh) 一种修饰的细胞及其用途
Shaha et al. Adoptive T‐cell therapies in the clinic
WO2021007266A1 (en) Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies
Džafo et al. DNA-dependent protein kinase inhibitors PI-103 and samotolisib augment CRISPR/Cas9 knock-in efficiency in human T cells
RU2808817C2 (ru) Способы получения из опухоли обогащенных популяций реактивных в отношении опухоли т-клеток
McCaw et al. Regenerative Immunotherapy for Cancer: Transcription Factor Reprogramming of Tumor-Specific T Cells